Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Amgen has launched its Eylea biosimilar, Pavblu (aflibercept-ayyh), after a victory in October in its patent fight with Regeneron. Fierce Pharma reported that a trio of US circuit judges on Oct. 22...
Korea’s Samsung Bioepis and Biogen, of Cambridge, Massachusetts, announced Nov. 18 that the European Commission had granted marketing authorization for Opuviz (aflibercept-yszy), an Eylea biosimila...
Swiss drugmakerSandoz announced Nov. 15 that the European Commission had granted marketing authorization for Afqlir (aflibercept), an Eylea biosimilar. Afqlir, available as a 2 mg vial kit and pre-...
Europe’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions on Sept. 19 for two new aflibercept (Eylea) biosimilars—Afqlir from Swiss drugmaker Sandoz and Opuviz, which ...
The FDA has approved Amgen’s Pavblu (aflibercept-ayyh), making it the fifth Eylea biosimilar to reach the milestone in the US in 2024. FDA records show Pavblu was approved Aug. 23. Labeling shows i...
Europe’s Committee for Medicinal Products for Human Use (CHMP) issued positive opinions on Sept. 19 for two new aflibercept (Eylea) biosimilars—Afqlir from Swiss drugmaker Sandoz and Opuviz, which ...
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....
Swiss drugmaker Sandoz announced Aug. 12 that the US FDA had approved Enzeevu, an aflibercept (Eylea) biosimilar, for wet age-related macular degeneration (AMD). Enzeevu (aflibercept-abzv) will be ...
Germany’s Novaliq announced July 29 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for Vevi...
Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Altos Biologics has submitted a marketing authorization application to the European Medicines Agency (EMA) for ALT-L9, an aflibercept (Eylea) biosimilar, according to a joint announcement by Altos ...
German companies Formycon and Klinge Biopharma announced June 28 that the US FDA had approved their aflibercept (Eylea) biosimilar for wet age-related macular degeneration (AMD), diabetic macular e...
The FDA announced May 20 that it had approved the US’ first interchangeable biosimilars to Eylea (aflibercept)— Yesafili, from India’s Biocon Biologics, and Opuviz, which was jointly developed by B...
AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...
Partners Xbrane Biopharma, of Sweden, and Germany’s Stada announced May 10 that they had entered into an exclusive licensing agreement with biosimilar company Valorum Biologics to market their rani...
Sweden’s Xbrane Biopharma announced April 21 that the US FDA had issued a complete response letter rejecting Xbrane’s ranibizumab biosimilar, branded in Europe as Ximluci. The company said regulato...
A US FDA official has expressed support for measures before Congress to remove the interchangeability designation for biosimilars, claiming that the two-tier system is only causing confusion. It ca...
A US FDA official has expressed support for measures before Congress to remove the interchangeability designation for biosimilars, claiming that the two-tier system is only causing confusion. Under...
Germany’s Formycon announced March 11 that FYB201 (ranibizumab), a biosimilar to Lucentis, had received marketing authorization from the Saudi Food & Drug Authority. Jordan’s MS Pharma is Formycon’...
UK-headquartered Immunocore reported Feb. 28 that its 2023 net product revenue from Kimmtrak (tebentafusp) was $238.7 million, a 70 percent increase over $140.7 million in 2022. The 2023 total was ...
Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...
Swedish biosimilar drug developer Xbrane reported Jan. 22 a rights issue of units to raise SEK 343 million ($32.8 million, converted on Jan. 22, 2024) in funding. Xbrane said the offering primarily...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Enzene Biosciences announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references Lucentis, which is sol...
India’s Biocon Biologics announced Sept. 20 that the European Commission had granted marketing authorization in the European Union for Yesafili, an aflibercept (Eylea) biosimilar. Yesafili is appro...
Coherus BioSciences announced Oct. 4 that sales of Cimerli (ranibizumab-eqrn), its Lucentis biosimilar, have exceeded 100 thousand doses since its US commercial launch on Oct. 3, 2022. Cimerli was ...
India’s Biocon Biologics announced Sept. 20 that the European Commission had granted marketing authorization in the European Union for Yesafili, an aflibercept (Eylea) biosimilar. Yesafili is appro...
Horizon Therapeutics, of Dublin, Ireland, reported Aug. 8 that its Q2-2023 Tepezza net sales totaled $446 million, a 7 percent decrease from $479.8 million in Q2-2022. The company said expansion of...
Sweden’s Xbrane Biopharma and its partner Stada, of Germany, announced July 24 that they were looking for a new partner to commercialize their ranibizumab biosimilar in the US and Canada, after the...
India’s Biocon Biologics announced July 24 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending approval of Yesafili...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.